Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647802 | 0.76 | NPC1 (0.44) | NPC1RAB9AKMT2AHSPA5PRMT5 | |
| SCHEMBL7196095 | 0.73 | NPC1 (0.46) | NPC1RAB9AKMT2AHSPA5PRMT5 | |
| SCHEMBL11599997 | 0.72 | NPC1 (0.46) | NPC1RAB9AKMT2AHSPA5 | |
| SCHEMBL28612372 | 0.72 | NPC1 (0.46) | NPC1RAB9AKMT2AHSPA5 | |
| SCHEMBL5161109 | 0.71 | NPC1 (0.42) | NPC1RAB9AKMT2AHSPA5FPR2 | |
| SCHEMBL6666888 | 0.71 | NPC1 (0.49) | NPC1RAB9AKMT2AHSPA5FPR2 | |
| SCHEMBL6281989 | 0.70 | NPC1 (0.47) | NPC1RAB9AKMT2AHSPA5 | |
| Hydrochloric Acid SCHEMBL17275457 | 0.70 | NPC1 (0.45) | NPC1RAB9AKMT2AHSPA5FPR2 | |
| Hydrochloric Acid SCHEMBL17275456 | 0.70 | NPC1 (0.45) | NPC1RAB9AKMT2AHSPA5FPR2 | |
| SCHEMBL7993393 | 0.70 | NPC1 (0.41) | NPC1RAB9AKMT2AHSPA5FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610663-B2 | Antisense compound with targeting and RNA cleaving moieties, preferably an imidazole functionality conjugated to the targeting oligonucleotide via linkers | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020160972-A1 | Compositions and methods for modulating RNA | ISIS PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6358931-B1 | OLIGONUCLETIDE CONJUGATED TO IMIDAZOLE; INTERCALATION AND COORDINATION COMPOUNDS; MEDICAL DIAGNOSIS, GENE THERAPY; ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| US-5514786-A | Compositions for inhibiting RNA activity | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0656790-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-14 | — | — | EP | disclosed |
| WO-1993017717-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160972-A1 | Compositions and methods for modulating RNA | RNGTT, NSUN3, NSUN2 | NPC1 3037/4885RAB9A 3848/4885KMT2A 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.